⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CMPX News
Compass Therapeutics, Inc. Common Stock
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
globenewswire.com
CMPX
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CMPX
Form 8-K
sec.gov
CMPX
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
globenewswire.com
CMPX
Form 8-K
sec.gov
CMPX
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
globenewswire.com
CMPX
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
globenewswire.com
CMPX
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
globenewswire.com
CMPX
Form 8-K
sec.gov
CMPX
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
prnewswire.com
CMPX
NKTX
GTBP
RXRX
FATE